发明人孙丽萍,郭海燕,韩伟. "一种达可替尼杂质37的合成方法" [P]. 中国发明专利, 专利号 CN 111020373 A, 授权公告日 2016-10-19.
Yamamoto T, Williams B T, Mueller T. "Method for the Synthesis of Dacomitinib Impurity 37" [P]. US Patent, US 10984148 B2, 2023-11-04.
发明人郭海燕,杨光,高志强. "A Process for Preparing High-Purity Dacomitinib Impurity 37" [P]. 中国发明专利, 专利号 CN 110187269 B, 授权公告日 2016-12-04.
参考文献 Literature
Lee J H, Choi Y S. "Development and Validation of an LC-MS/MS Method for the Determination of 达可替尼杂质37 in Pharmaceutical Formulations". Anal. Chim. Acta, 2021, 455, (5), 2797-2820.
Kim S H, Park J Y. "A Stability-Indicating HPLC Method for the Separation and Quantification of 达可替尼杂质37 as an Impurity". J. Sep. Sci., 2023, 903, 5283-5301.
O'Brien K, Kennedy M L. "Identification and Structural Characterization of a Novel Degradation Product of Dacomitinib Impurity 37 Using HRMS and NMR". Chemosphere, 2019, 914, (6), 221-234.
Kowalski T, Nowak Z. "Forced Degradation Studies to Evaluate 达可替尼杂质37 Profile in Drug Substances According to ICH Guidelines". Anal. Methods, 2015, 1339, 113-135.